CRYPTOCOCCAL VACCINE

隐球菌疫苗

• 批准号: 3768888
• 负责人: J BENNETT
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3768888
• 关键词: Cryptococcus; HIV infections; cell capsule; drug design /synthesis /production; drug screening /evaluation; fungal vaccines; human subject; immunoconjugates; laboratory mouse; polysaccharides; tetanus toxoid

Intramuscular injection of vaccine containing 50 mcg of type A cryptococcal capsular polysaccharide (glucuronoxylomannan, GXM) covalently linked to tetanus toxoid was well tolerated in more than 70 volunteers known to be seropositive for HIV-1. CD4 <200, 200-500 and >500/cu mm. A single booster dose of 50 mcg will be given at 6 months and antibody titers followed one year. Followup of 50 vaccinated normal volunteers found that the 25 receiving the 50 mcg dose had a better preservation of IgG anti-GXM titer at 6 month follow up, the titer having fallen from 76 units at two weeks to 31 units, compared to the 25 volunteers receiving 25 mcg, who had a fall from 48 to 15 units/ml. Forty nine of the 50 normal volunteers have been bled at one year following initial immunization to determine persistence of antibody. IgG purified from a vaccinated normal volunteer was injected into mice at a dose which induced anti-GXM levels comparable to those obtained in vaccinated normal volunteers. When injected intravenously with serotype A Cryptococcus neoformans, the mice were significantly protected against infection and death.

肌肉注射含50微克A型疫苗 隐球菌壳多糖(葡醛酸木甘露聚糖，GXM) 与破伤风类毒素共价相关的患者中有70多人耐受性良好 已知的HIV-1血清阳性的志愿者。Cd&lt；200、200-500和 &gt；500/cu mm。一次50微克的强化剂量将在6个月内给予 抗体滴度随访一年。50例正常人群接种疫苗后的随访 志愿者发现，接受50微克剂量的25人有更好的 6个月后保存抗GXM抗体滴度，滴度 从两周前的76套降至31套，而两周前为25套 志愿者服用25微克，从48单位/毫升降至15单位/毫升。 50名正常志愿者中有49名在一年内失血 在初次免疫后，确定抗体的持久性。 从接种疫苗的正常志愿者中提纯的免疫球蛋白注射到小鼠体内 诱导抗GXM水平的剂量与 给正常志愿者接种疫苗。当静脉注射血清型时 一种新型隐球菌，小鼠对 感染和死亡。